Clinical Trial Update: Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004% [Phase 3]

View source ↗

Summary

A Phase 3 study comparing TRAVATAN to Travoprost Ophthalmic Solution (0.004%) for open-angle glaucoma and ocular hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• TRAVOPROST OPHTHALMIC SOLUTION (Travoprost)
• Travatan (travoprost)

Snippet

Sponsor: Alcon Research | Conditions: Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Status: WITHDRAWN